- Home
- TSHA vs CXM Comparison
TSHA vs CXM Comparison
Compare TSHA & CXM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSHA | CXM |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TSHA | CXM |
|---|---|---|
| Price | $4.49 | $6.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 9 |
| Target Price | ★ $10.56 | $9.89 |
| AVG Volume (30 Days) | ★ 2.7M | 1.5M |
| Earning Date | 02-25-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 180.38 |
| EPS | N/A | ★ 0.42 |
| Revenue | $6,310,000.00 | ★ $839,147,000.00 |
| Revenue This Year | N/A | $8.25 |
| Revenue Next Year | N/A | $3.44 |
| P/E Ratio | ★ N/A | $15.45 |
| Revenue Growth | N/A | ★ 6.48 |
| 52 Week Low | $1.05 | $6.48 |
| 52 Week High | $6.02 | $9.69 |
Technical Indicators
Market Signals| Indicator | TSHA | CXM |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 31.82 |
| Support Level | $4.50 | $6.48 |
| Resistance Level | $4.89 | $6.91 |
| Average True Range (ATR) | 0.31 | 0.21 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 12.06 | 10.04 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About CXM Sprinklr Inc.
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.